Search PubMed⌕ Search

Biomedical subjects

H D Snoddy

Publications and source records attributed to H D Snoddy.

At least 73 records · Page 4Linked to original sources
PubMed1979

The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.

Metergoline antagonized the elevation of serum corticosterone by quipazine in rats. The ED50 of metergoline was less than 0.1 mg/kg, ip, and the effects of a 3 mg/kg dose persisted for more than 24 h. Metergoline did not antagonize the elevation of serum corticosterone by theophylline or ketamine (i.e. did not prevent corticosterone release nonspecifically) and did not affect the concentration of quipazine in the brain. Since quipazine is a serotonin receptor agonist, the antagonistic effects of metergoline may have been due to competition with quipazine at serotonin receptor sites in the brain. Some other agents capable of blocking serotonin receptors also antagonzied the elevation of serum corticosterone by quipazine. These included LY53857, which gave complete blockade at 3 mg/kg, and cyproheptadine and spiperone, which gave significant but incomplete antagonism at 1 mg/kg. Methysergide at 3 mg/kg did not alter the effect of quipazine. Metergoline did not antagonize the elevation of serum corticosterone by other agents throught to act via serotoninergic mechanisms, namely fluoxetine, fenfluramine, L-5-hydroxytryptophan, N,N-demthyl-5-methoxytryptamine, and 1-(m-trifluoromethylphenyl)piperazine. Thus, the interactions between metergoline and quipazine may have occurred at receptors that are not serotonin receptors or that represent a subset of serotonin receptors not mediating the actions of serotoninergic agents other than quipazine.

Animals↗
PubMed1978

Effect of 1-(m-trifluoromethylphenyl)-piperazine on 3H-serotonin binding to membranes from rat brain in vitro and on serotonin turnover in rat brain in vivo.

1-(m-Trifluoromethylphenyl)-piperazine inhibited the specific binding of tritiated serotonin to membranes from rat brain in vitro at lower concentrations than did quipazine or MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine). In rats 1-(m-trifluoromethylphenyl)-piperazine decreased the concentration of 5-hydroxyindoleacetic acid (5-HIAA) without altering the concentration of serotonin in whole brain. The decrease in 5-HIAA was apparently due to a decrease in serotonin turnover, since 1-(m-trifluoromethylphenyl)-piperazine caused a slower decline in serotonin concentration after synthesis inhibition by alpha-propyldopacetamide and a slower accumulation of 5-HIAA after probenecid injection to block its efflux from brain. The decrease in serotonin turnover is an expected result of stimulating serotonin receptors in brain and has earlier been reported to occur with quipazine. Thus all of the results are compatible with the idea that 1-(m-trifluoromethylphenyl)-piperazine acts as a serotonin receptor agonist in rat brain.

Animals↗
PubMed1978

The effect of quipazine, a serotonin receptor agonist, on serum corticosterone concentration in rats.

Quipazine, a serotonin receptor agonist, increased serum corticosterone within 30 min after its i.p. injection (at 10 mg/kg) into rats; the effect persisted at 1 and 2 hrs, but not at 4 hrs. Elevation of serum corticosterone did not occur with a 1.25 mg/kg dose of quipazine but was dose-related over a 2.5-20 mg/kg dose range. The effect of quipazine was completely prevented by methergoline, a serotonin receptor antagonist. The effect of quipazine was present in rats pretreated with 5,7-dihydroxytryptamine to destroy serotonin nerves and was not enhanced (as was the effect of L-5-hydroxytryptophan) by fluoxetine pretreatment. These data are compatible with the idea that quipazine increases serum corticosterone as a consequence of direct stimulation of serotonin receptors in brain.

5,7-Dihydroxytryptamine↗
PubMed1978

Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart.

Prazosin hydrochloride injected i.p. into rats markedly increased MOPEG sulfate (3-methoxy-4-hydroxy-phenylethylene glycol sulfate) concentration in brain and the rate of MOPEG sulfate accumulation after probenecid. The increase in MOPEG sulfate was dose-related over a 5-40 mg/kg dose range. After a 20 mg/kg dose of prazosin, the increase in MOPEG sulfate was greater than after the same dose of phenoxybenzamine and persisted for up to 24 hr. The rate of metaraminol disappearance from rat brain after alpha-methyl-m-tyrosine injection and the decline in brain norepinephrine after inhibition of its synthesis by alpha-methyltyrosine injection were increased in rats pretreated with prazosin. These findings indicate that prazosin increased brain norepinephrine turnover, probably via compensation to central alpha adrenoceptor blockade. Prazosin increased sertonin and 5-hydroxy-indoleacetic acid concentration and slightly decreased 3,4-dihydroxy-phenylacetic acid in rat brain. Although prazosin had little effect on brain norepinephrine concentration, heart norepinephrine was depleted for up to 16 hr after a 20 mg/kg dose of prazosin, and the depletion at 4 hr was dose-related down to 2 mg/kg of prazosin. These biochemical changes may all result from prazosin's block of alpha adrenergic receptors.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1978

Effects of pre- and post-treatment with EXP 561 on the amine-depleting effects of p-chloroamphetamine and 6-hydroxydopamine in rats.

EXP 561, 4-phenyl-bicyclo(2,2,2)octan-1-amine hydrochloride monohydrate, antagonized brain serotonin depletion by p-chloroamphetamine and heart norepinephrine depletion by 6-hydroxydopamine in rats. The antagonism of p-chloroamphetamine action occurred with post- as well as pre-treatment with EXP 561. Simultaneous injection of EXP 561 with p-chloroamphetamine initially antagonized serotonin depletion but the effect diminished by 24 hrs. The antagonism of 6-hydroxydopamine action could be produced only by pre-treatment with EXP 561, post-treatment having no effect. When EXP 561 was injected simultaneously with 6-hydroxydopamine, its antagonistic effect did not decline with time. The duplications of these findings for the interpretation of data on uptake inhibitor antagonism of amine depletors are discussed.

Amphetamines↗
PubMed1977

Elevation of plasma corticosterone by swim stress and insulin-induced hypoglycemia in control and fluoxetine-pretreated rats.

Fluoxetine, a drug that inhibits serotonin inactivation by reuptake from the synaptic cleft and thereby enhances serotonin nerve function, was used to study the possible role of serotonin neurons in the activation of the pituitary-adrenal system of rats by swim stress or insulin-induced hypoglycemia. Fluoxetine pretreatment enhanced the elevation of plasma corticosterone produced by injection of L-5-hydroxytryptophan but did not significantly alter the elevation of plasma corticosterone by swim stress or by insulin-induced hypoglycemia, even when the stimulus was shown to be submaximal. The results suggest that serotonin neural pathways postulated to stimulate ACTH secretion are not involved in the activation of adrenocortical function by these stimuli.

5-Hydroxytryptophan↗
PubMed1977

Biphasic effects of m-chlorophenyl-piperazine on 3,4-dihydroxyphenylacetic acid concentration in rat brain.

m-Chlorophenyl-piperazine dihydrochloride injected i.p. into rats caused a rapid increase and a subsequent decrease in whole brain concentration of 3,4-dihydroxyphenylacetic acid (DOPAC), a metabolite of dopamine. The increase in DOPAC at 30 min and the decrease at 3 hrs were dose-related and occurred after doses as low as 5 mg/kg of m-chlorophenyl-piperazine dihydrochloride.

3,4-Dihydroxyphenylacetic Acid↗